EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS (ECILC) fair value: what the stock is really worth

We calculate from audited financials what EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.

  1. Fair value above price? Yes
  2. Good quality? No
  3. Add to watchlist

Healthcare · TR · ISIN TRAECILC91E0

EE Thin data Sep 22, 2026

EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS

ECILC · IS

Low PriorityQuality growthFair Value upside is limited and quality is weak.

·Fair value 66.66 TRY · Fairly valued (+6%)
!Quality 49/100
!Mixed Growth (revenue 5y +61.1 %/yr)
!Loss over the last twelve months · -8.6% net margin (TTM) · fiscal year 2025 21.2%
Low debt · generates free cash flow
·2.36% dividend yield
!Mixed vs. peers (5/11)
!Narrow moat 14/100
!Evidence only low, so the estimate is less certain
Watch EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

128.62 TRY 5.03 TRY Fair Value 66.66 TRY Jun 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 22, 2026.

How to read this chart

60‑month range 5.03 TRY – 128.62 TRY · fair‑value band 50.00 TRY – 71.47 TRY · the 63.10 TRY price screens below the 66.66 TRY fair value. Dashed = 300-day average. As of Sep 22, 2026.

Which stocks are undervalued right now? Check free Discover now →

Company profile

EIS Eczacibasi Ilaç, Sinai ve Finansal Yatirimlar Sanayi ve Ticaret A.S., together with subsidiaries, engages in health and real estate development businesses in Turkey and internationally. The Health segment is involved in the production, marketing, and sale of medicines related to human health and veterinary medicines.

Show more

EIS Eczacibasi Ilaç, Sinai ve Finansal Yatirimlar Sanayi ve Ticaret A.S., together with subsidiaries, engages in health and real estate development businesses in Turkey and internationally. The Health segment is involved in the production, marketing, and sale of medicines related to human health and veterinary medicines. The Real Estate Development segment engages in development of real estate properties; rental activities for serum facilities; and providing consulting services on land development and project management. The company was incorporated in 1951 and is based in Istanbul, Turkey. EIS Eczacibasi Ilaç, Sinai ve Finansal Yatirimlar Sanayi ve Ticaret A.S. is a subsidiary of Eczacibasi Holding A.S.

Stock analysis

EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS (ECILC) currently trades at 63.10 TRY, while our model-based Fair Value estimate is 66.66 TRY, implying the stock looks roughly 5.3% fairly valued today.

Show more

Valuation

Bull case: the Growth Earnings group reads highest at a median of 75.42 TRY per share, and 7 of the 21 models we run sit above the 63.10 TRY price.

Bear case: the Multiples group reads lowest at 26.39 TRY, and 14 of the 21 models stay below the price. Evidence for this calculation is low.

Scenario range: 50.00 TRY (bear) to 71.47 TRY (bull), the price of 63.10 TRY sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 49/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS reported revenue of 9.9B TRL in FY2025 versus 1.1B TRL in FY2021, a compound +72.9%/yr. Reported net income was 2.1B TRL in FY2025, compounding +29.0%/yr from FY2021.

Key figures

Market cap 47.2B TRY (≈ $969M) · P/S ratio 4.80 · EPS (TTM) −1.24 TRY · Dividend yield 2.4% · Net margin 21.2% · Return on equity −1.5% · Return on assets (EBIT) 0.2% · Operating margin −11.1%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 39 out of 100 (low confidence).

What moves the price

The share trades about 51% below its 52-week high and 31% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −18% fair-value upside, at 6%, ECILC screens cheaper than that median.

Fair Value models

Bear 50.00 TRY Fair Value 66.66 TRY Bull 71.47 TRY
Model Each model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear Bear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull Bull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence Evidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
5Y EBITDA Exit 12.41 TRY 14.34 TRY 16.18 TRY 77
FCF DCF 29.11 TRY 48.28 TRY 98.18 TRY 76
Residual Income 65.29 TRY 63.86 TRY 55.41 TRY 76
All 21 models by family
DCF Models
FCF DCF 29.11 TRY 48.28 TRY 98.18 TRY 76
Owner Earnings 62.95 TRY 126.75 TRY 252.62 TRY 72
5Y Revenue Exit 23.01 TRY 38.27 TRY 60.28 TRY 71
5Y EBITDA Exit 12.41 TRY 14.34 TRY 16.18 TRY 77
5Y P/E Exit 44.80 TRY 87.65 TRY 141.18 TRY 68
10Y Revenue Exit 24.22 TRY 40.23 TRY 65.60 TRY 65
10Y EBITDA Exit 17.48 TRY 21.66 TRY 26.95 TRY 70
10Y P/E Exit 39.81 TRY 78.38 TRY 141.74 TRY 61
Earnings-Based
Graham-Dodd 20.73 TRY 128.10 TRY 178.79 TRY 63
Lynch FV 36.78 TRY 52.55 TRY 68.31 TRY 61
PEG = 1.0 36.78 TRY 52.55 TRY 68.31 TRY 57
Multiples
P/E Multiple 48.01 TRY 64.01 TRY 80.01 TRY 63
P/S Multiple 17.29 TRY 23.05 TRY 28.81 TRY 58
P/B Multiple 38.86 TRY 51.82 TRY 64.77 TRY 55
EV/EBITDA 5.45 TRY 5.50 TRY 5.56 TRY 67
EV/Revenue 20.06 TRY 26.39 TRY 32.72 TRY 54
Asset-Based
NCAV (Graham) 44.54 TRY 59.68 TRY 89.08 TRY 54
Growth DCF
Growth DCF 28.34 TRY 53.09 TRY 93.66 TRY 75
Rev-Margin DCF 23.01 TRY 37.76 TRY 58.75 TRY 71
Economic Profit
Residual Income 65.29 TRY 63.86 TRY 55.41 TRY 76
Growth Earnings
Growth-Adj P/E 52.80 TRY 75.42 TRY 98.05 TRY 67

Open the full fair value analysis →

Notify me when ECILC reaches fair value

Put ECILC on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 49/100

Of which business quality 53 · Market factors (momentum, volatility) 32

Profitability 30
Margins and returns on capital today
Quality Growth 48
Are margins and returns improving?
Cashflow 48
Earnings quality: real cash, not paper profit
Fin. Strength 78
Balance sheet, leverage, solvency risk
Investment 31
Disciplined investing over empire-building
Low Volatility 56
Calm price path (market factor)
Momentum 22
Price trend over the last 3–12 months (market factor)
52W Momentum 21
Distance to the 52-week high (market factor)
Net Issuance 82
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality Growth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 75/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−14.0%
Revenue growth 3 years Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+75.4%
Revenue growth 5 years Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+61.1%
Revenue growth 25 years Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−31.0%
What shareholders gained per year (last 5 years) What the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+47.7%
Earnings growth per share plus dividend.
Earnings per share, growth per year+45.3%
Dividend (yield on the price)2.4%
Profit margin 2020 to 2025 Operating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.13% → −9%

Growth Forecast

Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes This turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+30.6%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.

Watch ECILC, get fair value alerts →

Compare EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 608 stocks

Beats the industry median on 4/10 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 49 · Below median
Fair Value upside −32% · Below median
Profitability
Return on assets −1% · Below median
Net margin (TTM) −9% · Bottom 25%
Operating margin (TTM) −11% · Bottom 25%
Growth and dividend
Revenue growth −1% · Below median
Dividend yield (TTM) 2.4% · Above median
Balance sheet
Debt / equity 0.02× · Below median

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/S (TTM) 0.10× · Cheapest 25%
P/FCF 0.9× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)41 · sector 10
FUTURE (revenue growth)0 · sector 21
PAST (return on equity)0 · sector 25
HEALTH (low debt)99 · sector 97
DIVIDEND (yield)47 · sector 30

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Merck KGaA MRK €131.45 €106.48 −19%
Takeda Pharmaceutical Company TAK $18.64 $11.46 −39%
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥43.52 ¥47.87 +10%
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,854 ₹1,979 +7%
Galderma Group GALD CHF 154.05 CHF 109.10 −29%
Haleon plc HLN $9.21 $7.56 −18%
Teva Pharmaceutical Industries Limited TEVA $38.53 $15.33 −60%
Sandoz Group SDZ CHF 65.72 CHF 34.14 −48%
Zoetis Inc ZTS $73.00 $104.88 +44%
Hansoh Pharmaceutical Group 3692 HK$34.34 HK$37.77 +10%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS Fair Value". https://www.fairvalue-calculator.com/stock/ECILC

Frequently asked questions

Is EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS (ECILC) overvalued or undervalued?
As of Sep 22, 2026, our model estimates a fair value of 66.66 TRY versus a price of 63.10 TRY, about +6% upside (fairly valued).
What is the fair value of ECILC?
Our model-based fair value for EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS is 66.66 TRY (as of Sep 22, 2026), built from audited fundamentals. The current price: 63.10 TRY.
What is the quality score of ECILC?
EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS has a Quality Score of 49/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS (ECILC)?
Our model-based price target is the fair value of 66.66 TRY (as of Sep 22, 2026) from 21 valuation models. Cautious scenario 50.00 TRY, optimistic scenario 71.47 TRY. It is a calculation from audited fundamentals, not an analyst target.
What is the EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS stock forecast for 2026?
Our models put fair value at 66.66 TRY, about +6% upside versus a price of 63.10 TRY (fairly valued). Cautious scenario 50.00 TRY, optimistic scenario 71.47 TRY. The calculation is refreshed regularly with new filings.
What is the revenue of EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS (ECILC)?
EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS reported trailing-twelve-month revenue of about 9.8B TRY (latest available figure, as of Sep 22, 2026).
Does EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS pay a dividend?
EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS currently shows a dividend yield of about 2.36% relative to its recent price (as of Sep 22, 2026).
What growth is priced into EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS (ECILC)?
For today's price to be fair in a discounted-cash-flow model, EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS would have to grow free cash flow by +30.6 % per year for five years (discount rate 14.2 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +61.1 % per year. As of Sep 22, 2026.
What discount rate (WACC) does the fair value of ECILC use?
Our models discount EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS at 14.2 %: a base by market capitalisation (small), damped by beta 0.27, country premium for Turkey. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS that is +30.6 % per year a year over ten years, using the same discount rate (14.2 %) and the same formula as our fair value.
How much growth has EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS (ECILC) delivered so far?
Over the past 5 years revenue at EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS grew +61.1 % a year. The price currently implies +30.6 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS (ECILC) growing?
The median revenue growth in the sector is +2.9 % a year. That is the yardstick for the growth priced into EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS (+30.6 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS (ECILC)?
The free-cash-flow yield on the price is 2.83 %: that much free cash flow EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS produces per unit of market value. When it exceeds the discount rate of our models (14.2 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS (ECILC)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS it is 66.66 TRY per share (as of Sep 22, 2026), against a price of 63.10 TRY. It is the blended result of 21 valuation models (cash flow, earnings, asset, dividend).
Is EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS stock overvalued or undervalued in 2026?
As of Sep 22, 2026, ECILC trades below its calculated fair value: price 63.10 TRY, fair value 66.66 TRY, a gap of about +6% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ECILC?
No. The price is what the market pays today (63.10 TRY); the fair value is what the company's own numbers justify (66.66 TRY). For EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS the two are 3.56 TRY per share apart. That gap is exactly why we show both numbers side by side.
How much is EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS worth?
The market values EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS at about 47.2B TRY (market capitalisation, as of Sep 22, 2026). Per share that is 63.10 TRY; our models calculate a fair value of 66.66 TRY per share.
What do the bullish and bearish scenarios say about ECILC?
Our models span a range for EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS: cautious scenario 50.00 TRY, base 66.66 TRY, optimistic 71.47 TRY per share (as of Sep 22, 2026, price 63.10 TRY). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS (ECILC)?
Balance-sheet figures for EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS (as of Sep 22, 2026): return on equity −1.5%, debt of 0.02 per unit of equity. They feed the Quality Score of 49/100, which measures business quality independently of the share price.
How far is ECILC from its 52-week high?
EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS trades at 63.10 TRY, about 51% below its 52-week high of 129.89 TRY and 31% above the low of 48.23 TRY (as of Sep 22, 2026). Distance from the high says nothing about value: that is what the fair value of 66.66 TRY is for.
Which stocks are comparable to EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Jiangsu Hengrui Pharmaceuticals Co, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS stock attractive at the current price?
The data as of Sep 22, 2026: price 63.10 TRY, calculated fair value 66.66 TRY (+6%), Quality Score 49/100, from 21 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ECILC calculated?
We run EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS through 21 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 66.66 TRY, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 16.1 % above its aggregate fair value. EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS currently trades 6 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS (ECILC)?
The closing price on Sep 22, 2026 was 63.10 TRY. Our model-based fair value is 66.66 TRY, about +6% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS

How large is the market capitalisation of EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS (ECILC)?
The market capitalisation of EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS is 47.2B TRY (≈ $969M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS (ECILC)?
The price-to-sales ratio of EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS is 4.80 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS (ECILC)?
Earnings per share at EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS are −1.24 TRY. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS (ECILC)?
The dividend yield of EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS is 2.4%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS (ECILC)?
The net margin of EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS is 21.2% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS (ECILC)?
The return on equity (ROE) of EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS is −1.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS (ECILC)?
On an EBIT basis the return on assets of EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS is 0.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS (ECILC)?
The operating margin of EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS is −11.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS (ECILC)?
Revenue at EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS is growing −1.3% versus a year earlier (3y avg +75.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS (ECILC)?
Earnings per share at EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS are growing −51.2% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS (ECILC) carry?
The net debt of EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS is 948M TRY (fiscal year 2024, ≈ 0.9 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS in the live analysis

One click puts EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.